Amicus Therapeutics Inc. [NASDAQ: FOLD] surged by $0.39 during the normal trading session on Wednesday and reaching a high of $14.87 during the day while it closed the day at $14.77. The company report on September 24, 2020 that Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy.
Additional Phase 1/2 Data to be Presented at the Child Neurology Society Annual Meeting in October.
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to AT-GTX-501, the Company’s investigational gene therapy for children living with variant late infantile neuronal ceroid lipofuscinosis 6 (vLINCL6) disease, also known as CLN6 Batten disease.
Amicus Therapeutics Inc. stock has also gained 4.57% of its value over the past 7 days. However, FOLD stock has declined by -6.73% in the 3 months of the year. Over the past six months meanwhile, it has gained 47.21% and gained 51.59% year-on date.
The market cap for FOLD stock reached $3.99 billion, with 257.97 million shares outstanding and 231.76 million shares in the current float. Compared to the average trading volume of 1.99M shares, FOLD reached a trading volume of 1797936 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Amicus Therapeutics Inc. [FOLD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FOLD shares is $19.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FOLD stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Amicus Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 17, 2020. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price from $19 to $20. The new note on the price target was released on February 04, 2020, representing the official price target for Amicus Therapeutics Inc. stock. Previously, the target price had yet another raise from $18 to $20, while H.C. Wainwright kept a Buy rating on FOLD stock.
The Average True Range (ATR) for Amicus Therapeutics Inc. is set at 0.64, with the Price to Sales ratio for FOLD stock in the period of the last 12 months amounting to 17.60. The Price to Book ratio for the last quarter was 10.55, with the Price to Cash per share for the same quarter was set at 1.14.
FOLD stock trade performance evaluation
Amicus Therapeutics Inc. [FOLD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.57. With this latest performance, FOLD shares gained by 9.37% in over the last four-week period, additionally plugging by 47.21% over the last 6 months – not to mention a rise of 92.25% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 57.06, with the RSI for the last a single of trading hit 62.77, and the three-weeks RSI is set at 55.14 for Amicus Therapeutics Inc. [FOLD]. The present Moving Average for the last 50 days of trading for this stock 14.28, while it was recorded at 14.21 for the last single week of trading, and 12.10 for the last 200 days.
Amicus Therapeutics Inc. [FOLD]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Amicus Therapeutics Inc. [FOLD] shares currently have an operating margin of -165.03 and a Gross Margin at +85.33. Amicus Therapeutics Inc.’s Net Margin is presently recorded at -195.56.
Return on Total Capital for FOLD is now -44.51, given the latest momentum, and Return on Invested Capital for the company is -53.03. Return on Equity for this stock declined to -86.99, with Return on Assets sitting at -43.46. When it comes to the capital structure of this company, Amicus Therapeutics Inc. [FOLD] has a Total Debt to Total Equity ratio set at 44.13. Additionally, FOLD Total Debt to Total Capital is recorded at 30.62, with Total Debt to Total Assets ending up at 24.73. Long-Term Debt to Equity for the company is recorded at 42.62, with the Long-Term Debt to Total Capital now at 29.57.
Reflecting on the efficiency of the workforce at the company, Amicus Therapeutics Inc. [FOLD] managed to generate an average of -$610,253 per employee. Receivables Turnover for the company is 6.60 with a Total Asset Turnover recorded at a value of 0.22.Amicus Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.40 and a Current Ratio set at 3.50.
Earnings per share (EPS) analysis for Amicus Therapeutics Inc. [FOLD] stock
With the latest financial reports released by the company, Amicus Therapeutics Inc. posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.32/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 25.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FOLD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Amicus Therapeutics Inc. go to -1.00%.
Amicus Therapeutics Inc. [FOLD]: Insider Ownership positions
There are presently around $4,140 million, in the hands of institutional investors. The top three institutional holders of FOLD stocks are: PERCEPTIVE ADVISORS LLC with ownership of 25,182,364, which is approximately 0% of the company’s market cap and around 1.00% of the total institutional ownership; REDMILE GROUP, LLC, holding 24,944,695 shares of the stock with an approximate value of $368.31 million in FOLD stocks shares; and VANGUARD GROUP INC, currently with $356.02 million in FOLD stock with ownership of nearly -0.024% of the company’s market capitalization.
Positions in Amicus Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 119 institutional holders increased their position in Amicus Therapeutics Inc. [NASDAQ:FOLD] by around 19,166,847 shares. Additionally, 91 investors decreased positions by around 20,736,697 shares, while 34 investors held positions by with 240,509,382 shares. The mentioned changes placed institutional holdings at 280,412,926 shares, according to the latest SEC report filing. FOLD stock had 44 new institutional investments in for a total of 5,372,963 shares, while 18 institutional investors sold positions of 4,398,288 shares during the same period.